|
|
|
Clinical Research
This is the research conducted in collaboration
with patients.
It is intended to gain a better knowledge and then to be able to
treat intelligence genetic diseases
It includes :
Therapeutic Research
This is intended to study medicines which are aimed
at treating our patients. The clinical tests are conducted using
products in widespread use for other diseases. They are conducted
taking maximum precautions. In general this involves comparative
testing (double blind testing). Before implementation, the protocols
for these studies are subjected to multiple checks by the Jérôme
Lejeune Foundation Scientific Council, the French Ministry for
Research, the French National Committee for Information Technology
and Freedom (C.N.I.L.), the French Ministry of Health (AFSSaPS), the
Ethics Committee (C.C.P.P.R.B.), etc.
Several clinical tests are being conducted at the Jérôme Lejeune
Medical Centre :
ENTRAIN
concerns
children suffering from Trisomy 21 (Down's syndrome), between 3
and 30 months old.
TRAFAO
is being prepared, to
evaluate a long-term treatment for infants suffering from Trisomy
21.
COFAC
is being prepared, to study a
treatment intended for hyperactive 5- to 11-year old children
suffering from Trisomy 21.
TEDDI
is also being prepared, and
is aimed at adult patients suffering from Trisomy 21.
|
Epidemiological Research
These studies are essential in order to gain a
better knowledge of the diseases and are extremely valuable for
guiding future research, including the discovery of new medicines.
Epidemiological studies are under way at the Jérôme Lejeune Medical
Centre :
NICOLAS (metabolic
study) and
TROPHEE
(ophthalmological
study) are aimed at adult patients (over 18 years old).
The DULAC study
concerns a
particular form of epilepsy (infantile spasms) in children
suffering from Trisomy 21.
The SATGE study
concerns the
appearance of certain tumours in Trisomy 21.
TREFHOR
is conducted in Grenoble
and is studying the adaptation to physical exercise in adolescent
patients (13 to 18-year olds) suffering from Trisomy 21.
Finally, a very broad epidemiological study concerning all
patients suffering from Trisomy 21,
INTREPID is currently being elaborated.
|
Diagnostic Research
The RMLX study is
intended to improve the diagnostics of certain mental deficiencies,
where the gene is located on the X chromosome.
|
|
|
